BioNumerik Initiates Treatment of Patients in Global Phase III Clinical Trial of Tavocept(TM) to Confirm Substantial Survival Increases Previously Observed in Most Common Type of Lung Cancer
BioNumerik Pharmaceuticals, Inc.
Public Relations Department
(210) 614-1701, ext. 500
You May Also Like